Expert panel outlines conditions for AI-assisted ARIA detection on MRI

A multidisciplinary panel of neuroradiologists and Alzheimer disease clinicians reviewed evidence on AI-based tools for detecting amyloid-related imaging abnormalities (ARIA) during anti-amyloid antibody therapy monitoring. The panel concluded such tools are likely to enhance patient safety when used as clinical decision support within a radiologist-in-the-loop framework, but noted substantial variation among commercial tools in regulatory status, technical capability, and validation evidence, and called for further studies on clinical outcomes. The panel supported conditional implementation with radiologist oversight, quality assurance, and prospective performance monitoring.

Most relevant for: Clinicians and imaging teams involved in surveillance MRI monitoring of patients receiving amyloid-targeted monoclonal antibody therapy for early Alzheimer disease.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.